Brielle Benyon

We want to hear from nurses what your institutions are doing to safeguard employees and patients against the coronavirus, as well as common patient questions you’ve been receiving.

Enhanced navigation led some high-risk patients to an earlier breast cancer diagnosis, according to recent research.

The FDA, CDC, and NIOSH worked together to allow industrial-grade respirators to be used by healthcare workers to mitigate their risk of contracting the coronavirus.

Electronic medical records are helpful when treating patients with CAR T-cell therapy. However, many systems still are not designed for this type of treatment and need to be improved.

Oncology Nursing News will be speaking with experts on the matter, and we want to hear from our audience what kind of questions you have.

ASCO recently issued practice guidelines for pathologic diagnosis of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) to help healthcare practitioners better this rare disease.

The Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) plus pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who had 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Graft-versus host disease has improved in recent years, but there is still more work to be done.

Adolescent and young adult patients fall between the 2 age groups that clinicians are used to seeing, leading to gaps in care and poor outcomes.

Patients on Medicaid do not have coverage for routine care on clinical trials. However, the bipartisan Clinical Treatment Act is looking to change that.

The FDA granted a priority review to a supplemental biologics license application for frontline atezolizumab in patients with advanced non-squamous non-small cell lung cancer.

Preliminary durability results of the EV-103 study show that the combination of enfortumab vedotin and pembrolizumab may be a promising option for patients with locally advanced or metastatic urothelial carcinoma.

Clinicians should consider patient-related factors, disease-related factors, and prior therapies before deciding on a treatment regimen for patients with relapsed/refractory myeloma.

The FDA granted a priority review for the biologics license application for lisocabtagene maraleucel (liso-cel), to treat adults with relapsed or refractory large B-cell lymphoma.

Understanding nutritional status and patient cues is crucial in ensuring patients have the proper interventions and treatment plans.

Recent years have brought landmark changes to the treatment of advanced lung cancer, but there is still more work to be done.

Study findings, “changed how we see and treat patients with ovarian cancer,” said one expert.

Oncology Nursing News contributor, Donna Clark, RN, BSN, OCN, passed away on February 4, 2020, leaving a lasting legacy on the world of oncology nursing.

There are gaps in knowledge between socioeconomic and education status regarding cancer knowledge, according to a survey conducted in honor of World Cancer Day.

The use of liquid biopsies can expand in the world of oncology, according to Benjamin P. Levy, MD.

Compassion fatigue leads to high nursing turnover, and can also affect patient care, according to recent research.

Relationships between nurses and patients can be nuanced, and we want to hear what you think about interacting on social media.

Certain GE Healthcare Clinical Information Central Stations and Telemetry Servers may be compromised, according to the FDA.

Biosimilars are moving into the breast cancer treatment space, and have potential to bring costs down, but the hard numbers are still to be determined.

Nurses and other healthcare practitioners should discontinue use of Cardinal Health surgical gowns and packs, according to the agency.

In this special edition podcast, we spoke with both a physician and a nurse about the management of immune-related adverse events in patients with melanoma.

We asked our audience about what kind of cancer advancements they wish to see in the next 10 years. Here’s what they had to say.

See what your peers voted to be the top cancer advancements of the decade!

The FDA approved pembrolizumab (Keytruda) for the treatment of patients who are unresponsive to Bacillus Calmette-Guerin (BCG) treatment with high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.